Skip to content

Large-scale Brain Organization During Cognitive Control in ADHD

Large-scale Brain Organization During Cognitive Control in ADHD

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04349917
Enrollment
37
Registered
2020-04-16
Start date
2016-12-16
Completion date
2020-03-14
Last updated
2021-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder

Keywords

methylphenidate, functional connectivity, graph theory, cognitive control

Brief summary

The purpose of this study is to test whether children with attention-deficit/hyperactivity disorder (ADHD) are impaired in the ability to flexibly adapt brain network organization in response to shifting cognitive demands during the exertion of cognitive control, by assessing changes in network dynamics resulting from stimulant administration in children with ADHD, and how those changes relate to behavioral and symptom improvements. Subjects will be children with ADHD aged 8-12. Subjects will participate in multiple testing sessions that include: diagnosis and eligibility screening, neuropsychological and behavioral testing, and, if eligible, MRI scans and a medication challenge. Children with ADHD who are enrolled in the medication challenge will undergo one MRI scan on placebo and one MRI scan on stimulant medication, counterbalanced and double-blind. Functional connectivity will be measured using functional MRI and innovative graph theoretical analytic tools will be implemented. Network metrics will be related to symptomatology and behavioral testing measures. It is hypothesized that stimulant administration in children with ADHD will increase flexibility in network reconfiguration in response to changing cognitive control demands as compared to when they are on placebo. It is further hypothesized that the degree to which brain network organization is changed will be related to the degree of improvement in cognitive control performance.

Interventions

DRUGMethylphenidate

A single, low dose of methylphenidate (0.3 mg/kg) will be administered on the drug day.

OTHERPlacebo

A matching placebo pill will be administered on the placebo day.

Sponsors

National Institute of Mental Health (NIMH)
CollaboratorNIH
University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Masking description

The pharmacy that provides the drug/placebo works from a randomized subject order defining whether each subject received drug first or placebo first. Only the pharmacists know this order, and the drug and placebo look identical to the participants and the investigators.

Intervention model description

Randomized, double-blind, placebo-controlled, crossover design. Each subject with ADHD participates in two sessions, one on drug and one on placebo (order randomized ). Both subjects and experimenters are blind to the order.

Eligibility

Sex/Gender
ALL
Age
8 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* Between 8-12 years old * Diagnosis of ADHD (for ADHD group); ADHD group only can have comorbid Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnoses of oppositional defiant disorder, conduct disorder, depressive disorders, or anxiety disorders * ADHD subjects must never have been treated with medication for their ADHD

Exclusion criteria

* Wechsler Intelligence Scale for Children-Fifth Edition Full-Scale Intelligence Quotient (IQ) \< 80 * Wechsler Individual Achievement Test-Third Edition Word Reading \< 85 * Any neurologic or developmental disabilities * Any reading or learning disabilities * Visual impairment that cannot be corrected-to-normal * Color blindness * Documented hearing impairment greater than 25 decibels (dB) loss in either year * Have already gone through puberty (Tanner Stage II or higher) * Medical contraindication to MRI * Any psychoactive medication

Design outcomes

Primary

MeasureTime frameDescription
Resting State Brain Network Organization1 to 3 hours after administration of interventionAssessment of network topology during a resting state using functional connectivity estimates. Modularity will be determined by applying graph theoretical methods to functional connectivity estimates acquired during functional magnetic resonance imaging (fMRI) scans. Modularity is measured on a -1 to 1 scale, with higher scores indicating stronger community structure, or a stronger tendency of clusters of brain regions to separate into distinct, highly interconnected networks with sparse connections across networks. The optimal modularity value depends on the context. For example, during complex tasks lower modularity is better, while during basic, automatic tasks higher modularity is better.
Task-Based Brain Network Organization1 to 3 hours after administration of interventionAssessment of network topology during the Go/No-go (GNG) regular and GNG reward tasks. Subjects see a series of sports balls and are told to respond to most balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. Graph theoretical methods are applied to functional connectivity estimates from fMRI scans to determine modularity during each task. Modularity (-1 to 1 scale) measures the degree to which the whole-brain system separates into distinct communities, such that greater modularity reflects stronger community structure, or stronger tendency of brain regions to separate into distinct, highly interconnected networks with few connections across networks. Optimal modularity value depends on context. During complex tasks lower modularity is better, while higher modularity is better for basic tasks.
Rest-Task Reconfiguration1 to 3 hours after administration of interventionAssessment of reconfiguration of network topology between the GNG regular task and the resting state and GNG reward task and resting state. In the GNG tasks, subjects see a series of sports balls and are told to respond to most of the balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. Normalized mutual information will be determined by applying the same graph theoretical methods to functional connectivity estimates acquired during fMRI scans for each rest-task pair. Normalized mutual information is measured on a 0 to 1 scale, with higher scores indicating more similarity in network structure across task and rest conditions.
Drug-induced Normalization1 to 3 hours after administration of interventionAssessment of how changes in brain network topology relate to improvements in behavioral performance on the GNG regular and reward tasks, in which subjects respond to go stimuli and withhold responses to no-go stimuli. GNG tasks are identical, except subjects are rewarded for good performance on the reward task. Brain measures include change in modularity during rest, GNG regular, and GNG reward (Outcome Measures 1, 2); behavioral measures include change in commission rate, omission rate, and coefficient of variation of response time during GNG tasks (Outcome Measures 5-7). Pearson correlations are used to relate change in brain measures with change in behavioral measures from the placebo to the methylphenidate scans. Positive correlations indicate that subjects with greater change in the brain measure had greater change in the behavioral measure. Negative correlations indicate that subjects with less change in the brain measure had greater change in the behavioral measure.

Secondary

MeasureTime frameDescription
Go/No-go (GNG) Omission Rate1 to 3 hours after administration of interventionEvaluation of omission errors assessed during the GNG regular and GNG reward tasks. In the GNG tasks, subjects see a series of sports balls and are told to respond to most of the balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. In both tasks, omission errors occur on trials on which participants do not respond to a go stimulus to which they are supposed to respond. Omission errors are scored from 0 (no omission errors) to 1 (100% omission errors), with lower values indicating better performance.
Go/No-go (GNG) Response Time Variability1 to 3 hours after administration of interventionEvaluation of response time variability assessed during the GNG regular and GNG reward tasks. In the GNG tasks, subjects see a series of sports balls and are told to respond to most of the balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. Coefficient of variation (standard deviation / mean) will be calculated for response time in GNG regular and GNG reward tasks separately to account for group differences in mean response time.
Go/No-go (GNG) Commission Rate1 to 3 hours after administration of interventionEvaluation of commission errors assessed during the GNG regular and GNG reward tasks. In the GNG tasks, subjects see a series of sports balls and are told to respond to most of the balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. In both tasks, commission errors occur on trials on which participants respond to a stimulus (go response) when they are supposed to withhold a response (no-go trial). Commission errors are scored from 0 (no commission errors) to 1 (100% commission errors), with lower values indicating better performance.

Countries

United States

Participant flow

Recruitment details

Participants were recruited between December 2016 and March 2020.

Pre-assignment details

A total of 47 participants were screened during a behavioral visit. Of those not randomized, 8 did not meet inclusion criteria and 2 withdrew from study.

Participants by arm

ArmCount
Methylphenidate, Then Placebo
Participants received a single, low dose of methylphenidate (0.3 mg/kg) before the first MRI scan. Approximately one week later, participants received a matching placebo pill before the second MRI scan.
19
Placebo, Then Methylphenidate
Participants received a matching placebo pill before the first MRI scan. Approximately one week later, participants received a single, low dose of methylphenidate (0.3 mg/kg) before the second MRI scan.
18
Total37

Withdrawals & dropouts

PeriodReasonFG000FG001
First Intervention (2-4 Hours)Unable to Swallow Pill01
First Intervention (2-4 Hours)Withdrawal by Subject01

Baseline characteristics

CharacteristicMethylphenidate, Then PlaceboPlacebo, Then MethylphenidateTotal
Age, Continuous9.71 years
STANDARD_DEVIATION 0.92
9.75 years
STANDARD_DEVIATION 1.41
9.73 years
STANDARD_DEVIATION 1.17
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants1 Participants3 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
17 Participants16 Participants33 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants1 Participants1 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants1 Participants2 Participants
Race (NIH/OMB)
Black or African American
1 Participants0 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants3 Participants3 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
17 Participants14 Participants31 Participants
Region of Enrollment
United States
19 Participants18 Participants37 Participants
Sex: Female, Male
Female
9 Participants9 Participants18 Participants
Sex: Female, Male
Male
10 Participants9 Participants19 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 350 / 36
other
Total, other adverse events
11 / 359 / 36
serious
Total, serious adverse events
0 / 350 / 36

Outcome results

Primary

Drug-induced Normalization

Assessment of how changes in brain network topology relate to improvements in behavioral performance on the GNG regular and reward tasks, in which subjects respond to go stimuli and withhold responses to no-go stimuli. GNG tasks are identical, except subjects are rewarded for good performance on the reward task. Brain measures include change in modularity during rest, GNG regular, and GNG reward (Outcome Measures 1, 2); behavioral measures include change in commission rate, omission rate, and coefficient of variation of response time during GNG tasks (Outcome Measures 5-7). Pearson correlations are used to relate change in brain measures with change in behavioral measures from the placebo to the methylphenidate scans. Positive correlations indicate that subjects with greater change in the brain measure had greater change in the behavioral measure. Negative correlations indicate that subjects with less change in the brain measure had greater change in the behavioral measure.

Time frame: 1 to 3 hours after administration of intervention

Population: Participants excluded due to excessive head motion (mean framewise displacement \[FD\] \> 0.5 mm or fewer than 150 timepoints remaining after scrubbing all timepoints with FD \> 0.2 mm), incomplete brain coverage, or poor-quality fMRI data. Participants excluded if incomplete behavioral GNG data. Must have good data from both scan days to be included.

ArmMeasureGroupValue (NUMBER)
MethylphenidateDrug-induced NormalizationDelta GNG reg mod vs delta GNG reg RT variability-0.195 correlation coefficient
MethylphenidateDrug-induced NormalizationDelta rest mod vs delta GNG reg commission rate-0.361 correlation coefficient
MethylphenidateDrug-induced NormalizationDelta rest mod vs delta GNG reg omission rate0.508 correlation coefficient
MethylphenidateDrug-induced NormalizationDelta rest mod vs delta GNG reg RT variability0.287 correlation coefficient
MethylphenidateDrug-induced NormalizationDelta rest mod vs delta GNG rew commission rate0.162 correlation coefficient
MethylphenidateDrug-induced NormalizationDelta rest mod vs delta GNG rew RT variability0.003 correlation coefficient
MethylphenidateDrug-induced NormalizationDelta rest mod vs delta GNG rew omission rate-0.224 correlation coefficient
MethylphenidateDrug-induced NormalizationDelta GNG reg mod vs delta GNG reg commission rate-0.033 correlation coefficient
MethylphenidateDrug-induced NormalizationDelta GNG reg mod vs delta GNG reg omission rate-0.170 correlation coefficient
MethylphenidateDrug-induced NormalizationDelta GNG rew mod vs delta GNG rew commission rate0.220 correlation coefficient
MethylphenidateDrug-induced NormalizationDelta GNG rew mod vs delta GNG rew omission rate-0.276 correlation coefficient
MethylphenidateDrug-induced NormalizationDelta GNG rew mod vs delta GNG rew RT variability-0.027 correlation coefficient
Comparison: Change in rest modularity vs change in GNG regular commission ratep-value: 0.118Pearson correlation
Comparison: Change in rest modularity vs change in GNG regular omission ratep-value: 0.022Pearson correlation
Comparison: Change in rest modularity vs Change in GNG regular RT Variabilityp-value: 0.22Pearson correlation
Comparison: Change in rest modularity vs change in GNG reward commission ratep-value: 0.496Pearson correlation
Comparison: Change in rest modularity vs change in GNG reward omission ratep-value: 0.343Pearson correlation
Comparison: Change in rest modularity vs change in GNG reward RT variabilityp-value: 0.988Pearson correlation
Comparison: Change in GNG regular modularity vs change in GNG regular commission ratep-value: 0.892Pearson correlation
Comparison: Change in GNG regular modularity vs change in GNG regular omission ratep-value: 0.473Pearson correlation
Comparison: Change in GNG regular modularity vs Change in GNG regular RT Variabilityp-value: 0.409Pearson correlation
Comparison: Change in GNG reward modularity vs change in GNG reward commission ratep-value: 0.351Pearson correlation
Comparison: Change in GNG reward modularity vs change in GNG reward omission ratep-value: 0.238Pearson correlation
Comparison: Change in GNG reward modularity vs Change in GNG reward RT Variabilityp-value: 0.909Pearson correlation
Primary

Resting State Brain Network Organization

Assessment of network topology during a resting state using functional connectivity estimates. Modularity will be determined by applying graph theoretical methods to functional connectivity estimates acquired during functional magnetic resonance imaging (fMRI) scans. Modularity is measured on a -1 to 1 scale, with higher scores indicating stronger community structure, or a stronger tendency of clusters of brain regions to separate into distinct, highly interconnected networks with sparse connections across networks. The optimal modularity value depends on the context. For example, during complex tasks lower modularity is better, while during basic, automatic tasks higher modularity is better.

Time frame: 1 to 3 hours after administration of intervention

Population: Participants excluded due to excessive head motion (mean framewise displacement (FD) \> 0.5mm or fewer than 150 timepoints remaining after scrubbing all timepoints with FD \> 0.2mm), incomplete brain coverage, or poor-quality fMRI data. Participants must have good data from both methylphenidate and placebo scan days to be included in this analysis.

ArmMeasureValue (MEAN)Dispersion
MethylphenidateResting State Brain Network Organization0.223 units on a scaleStandard Deviation 0.026
PlaceboResting State Brain Network Organization0.228 units on a scaleStandard Deviation 0.034
p-value: 0.532t-test, 2 sided
Primary

Rest-Task Reconfiguration

Assessment of reconfiguration of network topology between the GNG regular task and the resting state and GNG reward task and resting state. In the GNG tasks, subjects see a series of sports balls and are told to respond to most of the balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. Normalized mutual information will be determined by applying the same graph theoretical methods to functional connectivity estimates acquired during fMRI scans for each rest-task pair. Normalized mutual information is measured on a 0 to 1 scale, with higher scores indicating more similarity in network structure across task and rest conditions.

Time frame: 1 to 3 hours after administration of intervention

Population: Participants excluded due to excessive head motion (mean framewise displacement \[FD\] \> 0.5mm or fewer than 150 timepoints remaining after scrubbing all timepoints with FD \> 0.2mm), incomplete brain coverage, or poor-quality fMRI data. Participants must have good data from both scan days and all tasks being compared to be included in this analysis.

ArmMeasureGroupValue (MEAN)Dispersion
MethylphenidateRest-Task ReconfigurationGNG reward0.122 units on a scaleStandard Deviation 0.074
MethylphenidateRest-Task ReconfigurationGNG regular0.104 units on a scaleStandard Deviation 0.055
PlaceboRest-Task ReconfigurationGNG regular0.119 units on a scaleStandard Deviation 0.058
PlaceboRest-Task ReconfigurationGNG reward0.150 units on a scaleStandard Deviation 0.074
Comparison: Analysis for reconfiguration between rest and GNG regular taskp-value: 0.296t-test, 2 sided
Comparison: Analysis for reconfiguration between rest and GNG reward taskp-value: 0.169t-test, 2 sided
Primary

Task-Based Brain Network Organization

Assessment of network topology during the Go/No-go (GNG) regular and GNG reward tasks. Subjects see a series of sports balls and are told to respond to most balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. Graph theoretical methods are applied to functional connectivity estimates from fMRI scans to determine modularity during each task. Modularity (-1 to 1 scale) measures the degree to which the whole-brain system separates into distinct communities, such that greater modularity reflects stronger community structure, or stronger tendency of brain regions to separate into distinct, highly interconnected networks with few connections across networks. Optimal modularity value depends on context. During complex tasks lower modularity is better, while higher modularity is better for basic tasks.

Time frame: 1 to 3 hours after administration of intervention

Population: Participants excluded due to excessive head motion (mean framewise displacement \[FD\] \> 0.5mm or fewer than 150 timepoints remaining after scrubbing all timepoints with FD \> 0.2mm), incomplete brain coverage, or poor-quality fMRI data. Participants must have good data from both methylphenidate and placebo scan days to be included in this analysis.

ArmMeasureGroupValue (MEAN)Dispersion
MethylphenidateTask-Based Brain Network OrganizationGNG regular0.213 units on a scaleStandard Deviation 0.041
MethylphenidateTask-Based Brain Network OrganizationGNG reward0.235 units on a scaleStandard Deviation 0.051
PlaceboTask-Based Brain Network OrganizationGNG regular0.218 units on a scaleStandard Deviation 0.04
PlaceboTask-Based Brain Network OrganizationGNG reward0.213 units on a scaleStandard Deviation 0.055
Comparison: Analysis for GNG regular taskp-value: 0.579t-test, 2 sided
Comparison: Analysis for GNG reward taskp-value: 0.034t-test, 2 sided
Secondary

Go/No-go (GNG) Commission Rate

Evaluation of commission errors assessed during the GNG regular and GNG reward tasks. In the GNG tasks, subjects see a series of sports balls and are told to respond to most of the balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. In both tasks, commission errors occur on trials on which participants respond to a stimulus (go response) when they are supposed to withhold a response (no-go trial). Commission errors are scored from 0 (no commission errors) to 1 (100% commission errors), with lower values indicating better performance.

Time frame: 1 to 3 hours after administration of intervention

Population: Participants must have good data from both methylphenidate and placebo scan days to be included in this analysis. Participants included if they completed at least one task.

ArmMeasureGroupValue (MEAN)Dispersion
MethylphenidateGo/No-go (GNG) Commission RateGNG regular0.396 units on a scaleStandard Deviation 0.213
MethylphenidateGo/No-go (GNG) Commission RateGNG reward0.292 units on a scaleStandard Deviation 0.176
PlaceboGo/No-go (GNG) Commission RateGNG regular0.403 units on a scaleStandard Deviation 0.206
PlaceboGo/No-go (GNG) Commission RateGNG reward0.348 units on a scaleStandard Deviation 0.181
Comparison: Analysis for GNG regular taskp-value: 0.806t-test, 2 sided
Comparison: Analysis for GNG reward taskp-value: 0.003t-test, 2 sided
Secondary

Go/No-go (GNG) Omission Rate

Evaluation of omission errors assessed during the GNG regular and GNG reward tasks. In the GNG tasks, subjects see a series of sports balls and are told to respond to most of the balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. In both tasks, omission errors occur on trials on which participants do not respond to a go stimulus to which they are supposed to respond. Omission errors are scored from 0 (no omission errors) to 1 (100% omission errors), with lower values indicating better performance.

Time frame: 1 to 3 hours after administration of intervention

Population: Participants must have good data from both methylphenidate and placebo scan days to be included in this analysis. Participants included if they completed at least one task.

ArmMeasureGroupValue (MEAN)Dispersion
MethylphenidateGo/No-go (GNG) Omission RateGNG regular0.071 units on a scaleStandard Deviation 0.116
MethylphenidateGo/No-go (GNG) Omission RateGNG reward0.040 units on a scaleStandard Deviation 0.055
PlaceboGo/No-go (GNG) Omission RateGNG regular0.104 units on a scaleStandard Deviation 0.119
PlaceboGo/No-go (GNG) Omission RateGNG reward0.101 units on a scaleStandard Deviation 0.111
Comparison: Analysis for GNG regular taskp-value: 0.093t-test, 2 sided
Comparison: Analysis for GNG reward taskp-value: 0.0001t-test, 2 sided
Secondary

Go/No-go (GNG) Response Time Variability

Evaluation of response time variability assessed during the GNG regular and GNG reward tasks. In the GNG tasks, subjects see a series of sports balls and are told to respond to most of the balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. Coefficient of variation (standard deviation / mean) will be calculated for response time in GNG regular and GNG reward tasks separately to account for group differences in mean response time.

Time frame: 1 to 3 hours after administration of intervention

Population: Participants must have good data from both methylphenidate and placebo scan days to be included in this analysis. Participants included if they completed at least one task.

ArmMeasureGroupValue (MEAN)Dispersion
MethylphenidateGo/No-go (GNG) Response Time VariabilityGNG regular0.298 coefficient of variationStandard Deviation 0.104
MethylphenidateGo/No-go (GNG) Response Time VariabilityGNG reward0.253 coefficient of variationStandard Deviation 0.071
PlaceboGo/No-go (GNG) Response Time VariabilityGNG regular0.344 coefficient of variationStandard Deviation 0.155
PlaceboGo/No-go (GNG) Response Time VariabilityGNG reward0.342 coefficient of variationStandard Deviation 0.146
Comparison: Analysis for GNG regular taskp-value: 0.075t-test, 2 sided
Comparison: Analysis for GNG reward taskp-value: 0.0001t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026